Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented porphyria cutanea tarda (PCT)~* Willing to give informed consent~* Age 18 or greater~Exclusion Criteria:~* Blistering skin lesions due to another condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Low-dose hydroxychloroquine 100 mg by mouth twice weekly
- Phlebotomy (Type: ACTIVE_COMPARATOR): Phlebotomy 450 mL biweekly

Based on this trial design, predict the completion outcome and termination type (if applicable).